Foundations Investment Advisors LLC Has $396,000 Stock Holdings in GSK plc (NYSE:GSK)

Foundations Investment Advisors LLC increased its holdings in shares of GSK plc (NYSE:GSK) by 15.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 11,717 shares of the pharmaceutical company’s stock after acquiring an additional 1,595 shares during the period. Foundations Investment Advisors LLC’s holdings in GSK were worth $396,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. AQR Capital Management LLC grew its stake in shares of GSK by 103.4% in the 2nd quarter. AQR Capital Management LLC now owns 26,363 shares of the pharmaceutical company’s stock valued at $1,015,000 after purchasing an additional 13,403 shares during the period. Creative Planning boosted its stake in GSK by 4.8% in the 2nd quarter. Creative Planning now owns 203,246 shares of the pharmaceutical company’s stock valued at $7,825,000 after buying an additional 9,322 shares in the last quarter. NewEdge Advisors LLC grew its position in GSK by 61.9% in the second quarter. NewEdge Advisors LLC now owns 70,048 shares of the pharmaceutical company’s stock valued at $2,697,000 after acquiring an additional 26,793 shares during the period. Sanctuary Advisors LLC acquired a new position in GSK during the second quarter worth $11,181,000. Finally, Newbridge Financial Services Group Inc. lifted its holdings in shares of GSK by 172.2% during the second quarter. Newbridge Financial Services Group Inc. now owns 3,103 shares of the pharmaceutical company’s stock valued at $119,000 after acquiring an additional 1,963 shares during the period. Institutional investors own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on GSK. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Six investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, GSK currently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Up 0.8 %

NYSE:GSK opened at $35.35 on Friday. The firm has a market capitalization of $73.27 billion, a price-to-earnings ratio of 22.96, a price-to-earnings-growth ratio of 1.31 and a beta of 0.63. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92. The stock’s 50 day moving average price is $34.01 and its two-hundred day moving average price is $37.73.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.